Salvage chemotherapy with paclitaxel, ifosfamide, and nedaplatin in patients with urothelial cancer who had received prior cisplatin-based therapy-Reference-Cited by-同舟云学术

Salvage chemotherapy with paclitaxel, ifosfamide, and nedaplatin in patients with urothelial cancer who had received prior cisplatin-based therapy

Published:2006-01-17 Issue:3 Volume:58 Page:402-407
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Shinohara Nobuo,Harabayashi Toru,Suzuki Shin,Nagao Kazuhiro,Seki Haruo,Murakumo Masashi,Mitsuhashi Kimiyoshi,Demura Takayoshi,Nagamori Satoshi,Matsuyama Hideyasu,Naito Katsusuke,Nonomura Katsuya

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-005-0175-4.pdf

Reference27 articles.

1. Sternberg CN, Yagoda A, Scher HI et al (1985) Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 133:403–407

2. Scher H (1989) Should single agents be standard therapy for urothelial tract tumors? J Clin Oncol 10:694–697

3. Roth BJ, Bajorin DF (1995) Advanced bladder cancer: the need to identify new agents in the post M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) world. J Urol 153:894–900

4. Sternberg CN (1995) The treatment of advanced bladder cancer. Ann Oncol 6:113–126

5. Loehrer P, Einhorn LH, Elson PJ et al (1992) A randomized comparison of cisplatin alone or in combination with methtrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10:1066–1073

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pre-first-line chemotherapy risk stratification for overall survival in advanced urothelial carcinoma in sequential therapy era;World Journal of Urology;2024-05-09

2. Comparison of Oncological Outcomes of Pembrolizumab as Second-line Therapy and Maintenance Avelumab Therapy in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy;Anticancer Research;2024-02-29

3. Outcome of maintenance systemic chemotherapy with drug-free interval for metastatic urothelial carcinoma;Japanese Journal of Clinical Oncology;2019-06-12

4. Changes in renal function following nedaplatin‑containing chemotherapy in patients with urothelial carcinoma unfit for cisplatin;Oncology Letters;2018-12-20

5. Outcome and prognostic factors in metastatic urothelial carcinoma patients receiving second-line chemotherapy: an analysis of real-world clinical practice data in Japan;Japanese Journal of Clinical Oncology;2018-06-25